All In Biotech

NDA 018893 · Hospira

Sodium Acetate

Sodium Acetate · Intravenous

Last checked: Nov 20, 2026Latest source record: Sep 2, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1983

May 4, 1983

Approved uses

1

Original approval plus efficacy supplements

Registered trials

232

60 Phase 3, 18 recruiting

FAERS reports

285

229 serious, 56 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 26, 2026.

INDICATIONS AND USAGE Sodium Acetate Injection, USP (2 mEq/mL) is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 4, 1983 Original approval · Type 5 - New Formulation or New Manufacturer
3 products under this application
  • SODIUM ACETATE · SODIUM ACETATE 40MEQ/20ML (2MEQ/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • SODIUM ACETATE · SODIUM ACETATE 100MEQ/50ML (2MEQ/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • SODIUM ACETATE · SODIUM ACETATE 200MEQ/100ML (2MEQ/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Sodium Acetate" as an intervention, any sponsor and status, largest first.

All 232 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use29
  • pyrexia23
  • nausea18
  • diarrhoea17
  • dyspnoea16
  • pneumonia16
  • vomiting16
  • death15
  • anaemia14
  • condition aggravated13
  • drug intolerance13
  • fatigue13

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
200512
20062
20073
20088
20092
20104
20116
20126
201314
20147
201511
20169
201714
201823
201926
202011
202125
202220
202314
202433
202515
202619

Recalls

1 FDA enforcement reports for this application.

  • Feb 26, 2013 · Class II · Terminated

    Lack of Assurance of Sterility: Loose crimp applied to the fliptop vial.

Shortages

FDA's drug shortage list.

  • Current · updated Nov 9, 2026

    Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-73).

  • Current · updated Nov 9, 2026

    Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-05).

  • Current · updated Nov 9, 2026

    Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-06).

  • Current · updated Nov 9, 2026

    Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-26).

  • Current · updated Nov 9, 2026

    Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-25).

  • Current · updated Nov 9, 2026

    Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-25).

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Sodium Acetate (Sodium Acetate)

2024 spending

$44K

Beneficiaries

42

501 claims

Per beneficiary

$1,059

$0.10 per unit

View as table
YearSpending
2020$11,881
2021$14,741
2022$24,938
2023$51,001
2024$44,487

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 62 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.